Close Menu
Home » Cynvenio, ATGen Initiate Pilot Study of Combo Cancer Test

Cynvenio, ATGen Initiate Pilot Study of Combo Cancer Test

Dec 28, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has launched a pilot surveillance study with South Korea's ATGen Global to evaluate a new method for the early detection of cancer recurrence in triple-negative breast cancer patients. Cynvenio's ClearID test will be combined with ATGen's NK Vue blood test to detect cancer recurrence in women who have previously been treated for triple-negative breast cancer and show no radiographic signs of metastases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Unexpected Close

GenomeWeb reports that Veritas Genetics is suspending its US operations.

Sweet Assembly

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Oh, You're Aging Well

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

Science Papers Describe MicroRNA Targeting Efficiency, Approach for Single-Cell High-Throughput Chemical Screens

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.

What's Popular?

In Business News

  1. Roche Ending Partnership With Syapse

  2. Veritas Genetics Halts US Operations, Lays Off More Than 30

  3. Illumina, PacBio Dispute UK Regulator's Finding That Merger Would Weaken Competition

  4. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

  5. Veracyte Exclusively Licenses NanoString Diagnostic Platform for Up to $60M

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.